CVS Health Co. (NYSE:CVS) is CapWealth Advisors LLC’s 9th Largest Position

CapWealth Advisors LLC lowered its position in shares of CVS Health Co. (NYSE:CVS) by 0.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 319,137 shares of the pharmacy operator’s stock after selling 2,923 shares during the quarter. CVS Health comprises approximately 3.1% of CapWealth Advisors LLC’s holdings, making the stock its 9th largest holding. CapWealth Advisors LLC’s holdings in CVS Health were worth $25,199,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Live Oak Investment Partners purchased a new position in CVS Health in the 4th quarter worth approximately $25,000. Atticus Wealth Management LLC boosted its holdings in shares of CVS Health by 149.0% during the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after acquiring an additional 219 shares during the period. Cornerstone Planning Group LLC boosted its holdings in shares of CVS Health by 111.5% during the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock valued at $32,000 after acquiring an additional 243 shares during the period. ZRC Wealth Management LLC boosted its holdings in shares of CVS Health by 400.0% during the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock valued at $39,000 after acquiring an additional 400 shares during the period. Finally, True Wealth Design LLC acquired a new position in shares of CVS Health during the fourth quarter valued at $48,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of CVS stock traded up $0.50 during trading hours on Thursday, reaching $69.10. 3,509,117 shares of the company’s stock were exchanged, compared to its average volume of 10,803,304. The business has a fifty day moving average price of $75.53 and a 200-day moving average price of $73.73. The company has a quick ratio of 0.63, a current ratio of 0.86 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $87.10 billion, a P/E ratio of 10.71, a P/E/G ratio of 0.91 and a beta of 0.52. CVS Health Co. has a fifty-two week low of $64.41 and a fifty-two week high of $83.25.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. The business had revenue of $93.81 billion during the quarter, compared to analyst estimates of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. CVS Health’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.99 earnings per share. Analysts predict that CVS Health Co. will post 8.32 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.85%. The ex-dividend date of this dividend is Friday, April 19th. CVS Health’s dividend payout ratio (DPR) is 41.18%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CVS. SVB Leerink assumed coverage on shares of CVS Health in a report on Monday, February 26th. They set an “outperform” rating and a $88.00 price target for the company. Piper Sandler lifted their price objective on shares of CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Barclays assumed coverage on shares of CVS Health in a research note on Wednesday, March 6th. They set an “equal weight” rating and a $78.00 price objective on the stock. Wells Fargo & Company cut their price objective on shares of CVS Health from $83.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 8th. Finally, Royal Bank of Canada cut their price objective on shares of CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a research note on Thursday, February 8th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $89.44.

Insider Buying and Selling at CVS Health

In other CVS Health news, EVP Prem S. Shah sold 29,473 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $76.95, for a total value of $2,267,947.35. Following the sale, the executive vice president now directly owns 39,765 shares in the company, valued at $3,059,916.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.24% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.